Carotenoids are colored natural pigments belonging to a large family of C40 skeleton with eight isoprene molecules.
Carotenoids are colored natural pigments belonging to a large family of C40 skeleton with eight isoprene molecules [1]. They are classified into xanthophylls and carotenes with the former such as lutein, β-cryptoxanthin and astaxanthin containing one or more oxygen atoms, while the latter such as α- carotene and β-carotene, lycopene and phytoene consisting of hydrogen and carbon atoms [2]. Carotenoid-rich foods have received great attention in human health due to their physiological functions such as antioxidant and anti-cancer as well as the ability to prevent chronic diseases such as age-associated macular degeneration and cardiovascular disease [3,4]. It has been well demonstrated that the functional properties of carotenoids were associated with their chemical structure i.e., the number of conjugated double bonds and the presence of different kinds of end-groups. However, these structural properties are also responsible for the carotenoid’s instability to light, high temperature, oxygen and metal ions, resulting in high susceptibility to oxidation and low bioavailability [3].
Given the multiple health benefits of carotenoids, they are widely used as a natural colorant and antioxidant in both pharmaceutical and food industries for prolonging shelf-life in dairy, meat, confectionary and beverage products [2]. However, carotenoids may undergo loss in functional properties during food processing owing to their instability and interaction with other food ingredients. Also the presence of digestive enzymes and some other nutrients in vivo as well as pH can alter carotenoid stability [4]. Consequently, it is vital to develop novel techniques to prevent carotenoid degradation for enhancement of bioavailability and bioactivity. Over the past decade, micro- and/or nano-encapsulation have emerged as imperative techniques for formulating food-based carotenoid carriers with improved physicochemical property and release behavior, as well as for prolonging blood circulation and efficient cellular uptake [2,5]. Comparatively, the microencapsulation technique fails to produce nanoparticles that are capable of penetrating into deeper portions of specific organs and tissues, resulting in poor bioavailability and bioactivity in vivo [6,7]. Thus, the transformation from microencapsulation to nanoencapsulation plays a pivotal role in reducing particles to nanosize by employing either top-down or bottom-up methods [8].
Recent advancements in the field of nanoscience and nanotechnology have enabled preparation of nanoscale functional compounds by encapsulating into a wide variety of nanostructures including nanoemulsions (NEs), nanoliposomes (NLs), nanocapsules (NCs), nanofibers (NFs), nanoparticles (NPs), solid lipid nanoparticles (SLNPs), nanostructured lipid carriers (NLCs) and supercritical fluid-based nanoparticles [4,5,9]. Based on the bibliometric search conducted in the Web of Science database (version 5.34) using keywords such as carotenoid nanoemulsion, carotenoid nanoparticle, carotenoid nanoencapsulation, carotenoid nanoliposome, carotenoid liposome, carotenoid micelle and carotenoid dispersion, the number of articles published from 2015-2020 was 441, of which the publications from 2019–2020 was higher (229) in terms of publication rate compared to that published between 2015–2018 (212). This trend is in line with the previous bibliometric studies [10,11]. Moreover, of the top 10 countries listed on research publications in carotenoid nanoencapsulation (2015–2020), China showed the highest publication output (23.7%) followed by USA (16.3%), Brazil (14.5%), Iran (14.5%), India (13.6%), while the other five countries including Saudi Arabia, Romania, Turkey, Pakistan and Italy, accounting for 17.4%, with an overall contribution from Asia, Europe and Americas being 60, 20 and 20%, respectively (Figure 1). Further analysis on difference in research characteristics among the top five highly-contributed countries during 2015–2020 showed that China (30) dominated with studies related to preparation and stability evaluation of nanocarotenoids, followed by Iran (20), India (19), USA (17) and Brazil (13). Likewise, most nanocarotenoid studies dealing with in vitro gastrointestinal release and bioavailability were from China (20), followed by USA (19), Iran (18), India (12) and Brazil (10). Many studies have also focused on fortification of nanoencpasulated carotenoids in a wide range of functional foods in dairy, bakery, and confectionary industries over last five years, with the top five countries accounting for 2.8–9.3% of total nanocarotenoid publications. For in vivo studies, although there was less publications by top 5 countries (5–22), a significant research output is apparent. Notably, China remained on the top with 22 publications dealing with determination of bioavailability and bioaccessibility, followed by USA (14), Iran/India (10 each) and Brazil (5). This highlights the need for many in vivo studies for proof-of-concept, functional validation, utility and clinical relevance of nanocarotenoids, which can be attained through promoting collaborative researches among institutes and countries for translation of nanocarotenoids into a botanic drug.
Reported studies on nanocarotenoids were mainly dealing with formulation of nanosized carotenoid carriers by nanotechniques, characterization and stability evaluation as well as determination of in vitro release behavior, bioaccessibility, bioavailability and biological activity [5].
Nanosystem | Carotenoids | Particle Size (nm) | EE (%) | Zeta Potential (mV) | Storage Stability (Days) | References |
---|---|---|---|---|---|---|
Nanoemulsions | β-carotene | 218 | NA | 40 | 21 at 37 °C | [32] |
143.7 | −38.2 | 30 at 25 °C | [33] | |||
Microbial carotenoids | 142.1 | NA | 30 at 25 °C | [34] | ||
Carotenoids | 290 to 350 | −53.4 to −58.8 | 21 at 25 °C | [35] | ||
β-carotene | 198.4 to 315.6 | −29.9 to −38.5 | 90 at 4, 25, and 37 °C | [36] | ||
Carotenoids | <200 | −30 to −45 | 35 at 25 °C | [37] | ||
Lycopene | 145.1 to 161.9 | −19.7 to −20.7 | 1 at 25 °C | [38] | ||
200.1 to 287.1 | 61 to 89.1 | 20 to 45 | 42 at 4, 25, and 37 °C | [39] | ||
Polymeric/biopolymeric NPs | Carotenoids | 153 | 83.7 | NA | NA | [40] |
84.4 | >96 | −41.3 to −43.6 | 60 at 41 °C | [41] | ||
β-carotene | 77.8 to 371.8 | 98.7 to 99.1 | −37.8 to −29.9 | NA | [42] | |
β-carotene | 70.4 | 97.4 | NA | NA | [43] | |
Lycopene | 152 | 89 | 58.3 | NA | [44] | |
~ 200 | >95 | −36 | 210 at 5 °C | [45] | ||
193 | NA | −11.5 | 14 at 25 °C | [46] | ||
Lutein | <250 | 74.5 | −27.2 | NA | [47] | |
Lutein | 240 to 340 | ~91.9 | NA | NA | [48] | |
Crocetin | 288 to 584 | 59.6 to 97.2 | NA | NA | [49] | |
Fucoxanthin | 200 to 500 | 47 to 90 | 30 to 50 | 6 at 37 °C | [50] | |
Nanoliposomes/liposomes | Carotenoids | 70 to100 | 75 | −5.3 | NA | [51] |
β-carotene | 162.8 to 365.8 | ~98 | 64.5 to 42.6 | 70 at 4 °C | [52] | |
Astaxanthin | 80.6 | 97.6 | 31.8 | 15 at 4 and 25 °C | [53] | |
60 to 80 | 97.4 | NA | NA | [54] | ||
Lutein | 264.8 to 367.1 | 91.8 to 92.9 | −34.3 to −27.9 | NA | [55] | |
SLNPs and NLCs | β-carotene SLNPs | 200 to 400 | 53.4 to 68.3 | −6.1 to −9.3 | 90 at 5, 25, and 40 °C | [56] |
<220 | NA | 20 to 30 | 10 at 25 °C | [57] | ||
120 | NA | −30 | 56 at 25 °C | [58] | ||
Lycopene SLNPs | 125 to 166 | 86.6 to 98.4 | NA | 60 at 4 °C | [59] | |
Lycopene NLCs | 157 to 166 | > 99 | −74.2 to −74.6 | 120 at 4, 30, and 40 °C | [8] | |
121.9 | 84.50 | −29 | 90 at 25 °C | [60] | ||
Supercritical fluid-based NPs | Astaxanthin | 150 to 175 | NA | NA | NA | [61] |
266 | 84 | NA | NA | [62] | ||
Metal/metal oxide-based NPs and hybrid nanocomposites | Carotenoids | 20 to 140 | NA | NA | NA | [63] |
Lycopene | 3 to 5 | −48.5 | 90 at 4 and 25 °C | [64] | ||
20.8 | −25.3 | NA | [65] |
Table 2. The advantages and disadvantages of nanosystems for encapsulation of carotenoids 1.
Nanosystem |
Advantages and Disadvantages |
References |
---|---|---|
Nanoemulsions |
Advantages
Disadvantages
|
|
Polymeric/biopolymeric NPs |
Advantages
Disadvantages
|
|
Nanoliposomes/liposomes |
Advantages
Disadvantages
|
|
SLNPs |
Advantages
Disadvantages
|
|
NLCs |
Advantages
Disadvantages
|
|
Supercritical fluid-based NPs |
Advantages
Disadvantages
|
|
Metal/metal oxide-based NPs and hybrid nanocomposites |
Advantages
Disadvantages
|
1 EE = encapsulation efficiency, NPs = nanoparticles, SLNPs = solid lipid nanoparticles and NLCs = nanostructured lipid carriers.
This entry is adapted from the peer-reviewed paper 10.3390/antiox10050713